175 related articles for article (PubMed ID: 12522042)
1. Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia.
Scagnolari C; Casato M; Bellomi F; De Pisa F; Turriziani O; Coviello R; Pirro MR; Dianzani F; Antonelli G
Clin Diagn Lab Immunol; 2003 Jan; 10(1):70-7. PubMed ID: 12522042
[TBL] [Abstract][Full Text] [Related]
2. Resistance to recombinant alpha interferon therapy in idiopathic mixed cryoglobulinemia: reinduction of remission by natural alpha interferon both in antibody-positive and -negative patients.
Casato M; Antonelli G; Maggi F; Pucillo LP; Di Lullo L; Leoni M; Currenti M; Dianzani F; Bonomo L
J Biol Regul Homeost Agents; 1994; 8(2):56-9. PubMed ID: 7863814
[TBL] [Abstract][Full Text] [Related]
3. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3.
Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A
Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083
[TBL] [Abstract][Full Text] [Related]
4. Rapid and simple detection of IFN-neutralizing antibodies in chronic hepatitis C non-responsive to IFN-alpha.
Jorns C; Holzinger D; Thimme R; Spangenberg HC; Weidmann M; Rasenack J; Blum HE; Haller O; Kochs G
J Med Virol; 2006 Jan; 78(1):74-82. PubMed ID: 16299717
[TBL] [Abstract][Full Text] [Related]
5. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha.
Wussow PV; Jakschies D; Freund M; Hehlmann R; Brockhaus F; Hochkeppel H; Horisberger M; Deicher H
Br J Haematol; 1991 Jun; 78(2):210-6. PubMed ID: 2064959
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-alpha on immunoparameters in vivo.
Davis-Daneshfar A; Böni R; von Wussow P; Joller H; Burg G; Dummer R
J Immunother; 1997 May; 20(3):208-13. PubMed ID: 9181459
[TBL] [Abstract][Full Text] [Related]
7. Induction of MxA mRNA in patients with neuroendocrine tumors after interferon treatment. Lack of correlation with antitumor response.
Imam H; Janson ET; Gobl A; Alm G; Oberg K
Anticancer Res; 1995; 15(5B):2191-5. PubMed ID: 8572623
[TBL] [Abstract][Full Text] [Related]
8. Therapy-induced antibodies against the antiviral and antiproliferative effects of interferons in patients with chronic hepatitis C virus infection.
Bálint E; Bakay M; Onody K; Farkas F; Horváth G; Tolvaj G; Dávid K; Horányi M; Béládi I
Acta Microbiol Immunol Hung; 2004; 51(3):359-69. PubMed ID: 15571075
[TBL] [Abstract][Full Text] [Related]
9. MxA induction may predict sustained virologic responses of chronic hepatitis B patients with IFN-alpha treatment.
Kong XF; Zhang XX; Gong QM; Gao J; Zhang SY; Wang L; Xu J; Han Y; Jin GD; Jiang JH; Zhang DH; Lu ZM
J Interferon Cytokine Res; 2007 Sep; 27(9):809-18. PubMed ID: 17892402
[TBL] [Abstract][Full Text] [Related]
10. Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment.
Rönnblom LE; Janson ET; Perers A; Oberg KE; Alm GV
Clin Exp Immunol; 1992 Sep; 89(3):330-5. PubMed ID: 1516252
[TBL] [Abstract][Full Text] [Related]
11. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.
Ross C; Svenson M; Hansen MB; Vejlsgaard GL; Bendtzen K
J Clin Invest; 1995 May; 95(5):1974-8. PubMed ID: 7738163
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies.
Scagnolari C; Duda P; Bagnato F; De Vito G; Alberelli A; Lavolpe V; Girardi E; Durastanti V; Trojano M; Kappos L; Antonelli G
J Neurol; 2007 May; 254(5):597-604. PubMed ID: 17420930
[TBL] [Abstract][Full Text] [Related]
13. IFN-alpha antibodies in patients with age-related macular degeneration treated with recombinant human IFN-alpha2a.
Ross C; Engler CB; Sander B; Bendtzen K
J Interferon Cytokine Res; 2002 Apr; 22(4):421-6. PubMed ID: 12034024
[TBL] [Abstract][Full Text] [Related]
14. Response to sequential treatment with lymphoblastoid interferon-alpha in patients with Ph+ chronic myeloid leukemia unresponsive to recombinant interferon-alpha (rIFN alpha 2a) and neutralizing-rIFN alpha 2a antibodies negative.
Russo D; Candoni A; Grattoni R; Minisini R; Rosti G
Haematologica; 1997; 82(3):348-50. PubMed ID: 9234589
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies to equine interferon-alpha (IFN-alpha): new tools to neutralize IFN-activity and to detect secreted IFN-alpha.
Wagner B; Hillegas JM; Flaminio MJ; Wattrang E
Vet Immunol Immunopathol; 2008 Oct; 125(3-4):315-25. PubMed ID: 18586327
[TBL] [Abstract][Full Text] [Related]
16. Treatment strategies for early-stage chronic lymphocytic leukemia: can interferon-inducible MxA protein and tumor necrosis factor play a role as predictive markers for response to interferon therapy?
Bezares F; Kohan S; Sacerdote de Lustig E; Farías E; Murro H; Horisberger MA
J Interferon Cytokine Res; 1996 Jul; 16(7):501-5. PubMed ID: 8836914
[TBL] [Abstract][Full Text] [Related]
17. Epitopes recognized by neutralizing therapy-induced human anti-interferon-alpha antibodies are localized within the N-terminal functional domain of recombinant interferon-alpha 2.
Nolte KU; Günther G; von Wussow P
Eur J Immunol; 1996 Sep; 26(9):2155-9. PubMed ID: 8814261
[TBL] [Abstract][Full Text] [Related]
18. Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-alpha subtypes.
Brand CM; Leadbeater L; Bellati G; Marotta F; Ideo G
J Interferon Res; 1993 Apr; 13(2):121-5. PubMed ID: 7685368
[TBL] [Abstract][Full Text] [Related]
19. Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy.
Antonelli G; Simeoni E; Turriziani O; Tesoro R; Redaelli A; Roffi L; Antonelli L; Pistello M; Dianzani F
J Interferon Cytokine Res; 1999 Mar; 19(3):243-51. PubMed ID: 10213463
[TBL] [Abstract][Full Text] [Related]
20. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors.
Oberg K; Alm GV
J Interferon Res; 1989 Sep; 9 Suppl 1():S45-9. PubMed ID: 2809277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
